Company ProfilePremium

Daewon Pharmaceutical Co., Ltd.

Company Profile Analysis

Ticker: 003220.KS대원제약 주식회사

ESOMAR 23 Corporate BadgeISO Certifications Badge
Daewon Pharmaceutical Co., Ltd. - Company showcase

Year Founded & Workforce

1958

1,349 Employees

Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Daewon Pharmaceutical Co., Ltd. Overview

Daewon Pharmaceutical is a second-to-third-generation family-controlled, mid-sized Korean prescription-drug company with consolidated FY2025 revenue of KRW 605.4bn [S1]. Its franchise rests on primary-care respiratory and pain medicines sold through a dense clinic (local doctor) sales network: the Codaewon antitussive-expectorant series, the in-house new drug Pelubi (pelubiprofen, Korea's 12th domestically developed new drug), and the Colday squeezable OTC cold-syrup range. The company is attempting a three-way pivot: (1) from seasonal respiratory products toward chronic-disease drugs (hypertension, diabetes, dyslipidaemia) via in-house combinations and co-promotions (Celltrion's Idalbi family, AstraZeneca's Symbicort); (2) from generics/incrementally modified drugs toward new chemical entities (P-CAB padoprazan in Phase 3; obesity programmes); and (3) into consumer health via acquired subsidiaries (Daewon Healthcare, SD Biotechnology). Profitability has collapsed (FY2025 operating margin 0.6%) as acquisitions, price cuts and R&D spend have offset top-line growth.


What the company does

Daewon manufactures and sells finished-dose pharmaceuticals in Korea across circulatory, respiratory, anti-infective, psychoneurological, digestive and analgesic categories, and exports to roughly 40 countries in Asia, Latin America, the Middle East, CIS and Africa [S31]. The company describes itself as a "pure therapeutic medicines" company founded on the corporate philosophy of "realising human health", producing more than 200 therapeutic products sold through a nationwide sales network [S33]. It now positions itself as a "comprehensive healthcare company" spanning prescription drugs (ETC), over-the-counter drugs (OTC), health functional foods (HFF), medical devices and cosmetics [S33][S14].

Company's own description (paraphrased from IR and corporate materials)

  • Leading position in Korea's respiratory prescription market, with the No.1 antitussive-expectorant (Codaewon S) and the No.1 NSAID by prescriptions since 2018 (Pelubi family) [S19].

  • Business evolution framed as "ETC → OTC → CHC (consumer healthcare) → cosmetics" [S19].

  • Strategic emphasis on expanding chronic-disease share and reducing seasonality [S21][S9].

Independent characterisation

Daewon is best understood as a primary-care commercial engine with a narrow profit pool. Roughly 87–90% of revenue is pharmaceuticals [S2][S1]; within that, respiratory and analgesic products (≈38% of FY2025 revenue combined) are highly exposed to (a) seasonal respiratory disease incidence and (b) Korean health-insurance price regulation. The company's competitive moat is its clinic-level sales reach (historically claimed as ~one-third of Korean local clinic transactions [S34]) and its large liquid/syrup manufacturing capacity at the Jincheon smart factory, which allowed it to capture share during the 2022–2024 pandemic/endemic cough-medicine surge [S35]. The moat is weaker on the innovation side: its only approved NCE (Pelubi, 2007) has lost patent exclusivity in practice and took a 47% reimbursement price cut in May 2026 [S36].

Business and revenue model

Revenue model componentDescriptionIndicative weight
Own-manufactured prescription productsGenerics, incrementally modified drugs (IMDs), combinations, one NCE (Pelubi); sold to clinics/hospitals via wholesalers and pharmaciesMajority of the pharma segment
In-licensed / co-promoted products ("merchandise")AstraZeneca Symbicort/Pulmicort (distribution and sales, royalty-bearing), Celltrion Idalbi family (co-sales)Rising; drives cost-of-goods inflation [S37][S20]
OTC brandsColday (cold), Potagel (antidiarrhoeal), pain/OTC liquidsOTC revenue >KRW 40bn annually (company claim, Sept 2025) [S19]
Health functional foodsDaewon Health brand B2C (Kkuljam Shot, Hair Collagen 3X, Albumin King etc.) plus contract manufacturing at Daewon HealthcareFY2025 KRW 36.1bn segment revenue [S1]
CosmeticsSD Biotechnology mask packs (≈79%) and eye patches (≈21%)FY2025 KRW 30.1bn [S1][S38]
Licensing / subscriptionNo material licensing-out income disclosedNot material

Customer types: clinics and hospitals (prescribers), community pharmacies, pharmaceutical wholesalers, home-shopping and online channels (HFF), ODM customers (Daewon Healthcare), export distributors.

Value-chain position: integrated developer–manufacturer–marketer; limited API manufacturing (not disclosed); relies on outsourced APIs and in-licensed finished products for part of the portfolio.

End-markets: Korean outpatient prescription market (primary-care), Korean OTC and HFF retail, export markets (~4–6% of revenue).

Strategy

Stated strategic themes (paraphrased)

  • Become a top-tier pharma company via new growth businesses and R&D (Vice Chairman's long-standing framing) [S91].

KRW 1 trillion revenue: originally targeted for 2025 when Baek In-hwan took office [S54]; recruitment-research summaries now cite a 2028 date [S73] (the revised date is not confirmed in a filing).

Chronic-disease pivot: raise circulatory/endocrine share of revenue to 35% by 2028 (from the 2024 baseline), led by the Idalbi family and in-house combinations [S21].

From generic leader to innovator: second in-house new drug (padoprazan) as the next growth engine [S40].

Consumer healthcare build-out: (HFF and cosmetics) to reduce seasonality [S9].

2H26 priorities: continue chronic-disease and HFF diversification while pursuing cost efficiencies to restore profitability [S6].

Initiatives in the last 24 months

InitiativeDateDetailSource
AstraZeneca inhaler partnershipFeb 2025Distribution/marketing/sales of Symbicort and Pulmicort Respules; royalty terms confidential[S37]
Pelubi life-cycle defenceJan 2025Pelubi S launch[S57]
P-CAB Phase 3 programmeOct 2025–Jan 2026ERD and NERD Phase 3; H. pylori combination Phase 1[S62][S92]
Celltrion Idalbi co-promotionJan 2026Three hypertension products[S20]
Twinclo launchApr 2026 (planned)Own triple hypertension combination[S21]
Obesity R&D2025–2026Quadruple agonist (ADA 2026), oral semaglutide (human trials planned 2027), DW-1022 patch[S63][S88]
Corporate venture capital2026 (planned)CVC to invest in digital-healthcare companies[S28]
Subsidiary restructuring2025–2026SD Biotech 60% capital reduction (par KRW 500→200), HFF plant sale, Magok building purchase, CEO change[S93][S85][S53]
Sinbaro in-sourcingSep 2026In-house production to unify production and sales[S25]
ESG2,025KCGS A rating; ISO 14001 / ISO 37001; ESG committee[S60]
Shareholder returns2024–2026Pay ≥15% of separate net income as dividends for 2024–2026; articles amended for dividend predictability[S58]

Medium-term targets / guidance

No formal numerical earnings guidance was found. Quantified targets: 35% chronic-disease revenue share by 2028 [S21]; 12 blockbuster products (KRW 10bn+ each) — achieved by 2024 per the KIR technical report [S94]; net-zero by 2050 with 40% GHG reduction by 2040 (secondary source) [S73].

Products & Services

Pricing is governed by Korea's National Health Insurance reimbursement ceiling for prescription drugs; OTC/HFF pricing is not disclosed.

Pharmaceuticals — Respiratory

ProductDescription / compositionTargetLaunch / statusKey data
Codaewon Forte (코대원포르테)Antitussive-expectorant suspension (dihydrocodeine-containing combination; ammonium chloride variant of Codaewon)Acute bronchitis/cough, primary careMid-2010sCodaewon series Rx KRW 56.6bn (2022), 80.4bn (2023), 93.2bn (2024) [S19]
Codaewon S syrup (코대원에스)Korea's first five-component antitussive-expectorant combination; Phase 3 superiority trial vs active controlCough/sputum2,020Rx KRW 34.3bn (2022), 51.9bn (2023), 70.1bn (2024) [S46]
Codaewon Plus tab (코대원플러스정)Codaewon + Pelargonium sidoides extractAcute bronchitisApproved Sep 2025; launch targeted Dec 2025Fourth Codaewon line extension [S69]
Privitus suspension (프리비투스현탁액)Antitussive (levodropropizine-class)CoughPouch re-production; supply resumed Oct 2026Combined with Codaewon S/Forte >KRW 100bn Rx, ~42% of a ~KRW 240bn cough-syrup market (2024) [S46][S25]
Comfona Compact Air (콤포나콤팩트에어)Fluticasone propionate/salmeterol DPIAsthma/COPD2,020Own inhaler in a ~KRW 130bn inhaler market [S47]
Symbicort Turbuhaler/Rapihaler (AZ)Budesonide/formoterolAsthma, severe COPDDistribution from Feb 20252024 Korea Rx KRW 17.7bn (company IR) [S19][S37]
Pulmicort Respules (AZ)Budesonide nebuliserPaediatric asthma, croupDistribution from Feb 20252024 Korea Rx KRW 8.3bn; 3-year CAGR 55% (2022–24) [S19][S37]

Pharmaceuticals — Pain / anti-inflammatory / musculoskeletal

ProductDescriptionTargetLaunchKey data
Pelubi tab (펠루비정)Pelubiprofen 30mg NSAID; Korea's 12th domestic new drugOsteoarthritis, RA, back pain, fever/acute upper respiratory painApproved Sep 2007; launched Oct 2008Pelubi family Rx KRW 41.2bn (2022), 47.5bn (2023), 62.2bn (2024), 57.2bn (2025) [S19][S36]. Ceiling price cut KRW 180→96 (−46.7%) from 1 May 2026 [S36]
Pelubi SR (펠루비서방정 / CR)Sustained-release pelubiprofenChronic pain—Price cut KRW 304→234 (−23.0%) from 1 May 2026 [S36]
Pelubi S tab (펠루비에스정)Life-cycle extension of PelubiPainJan 2025Defensive line extension [S57]
Sinbaro (신바로)Natural-product osteoarthritis drugOsteoarthritisDaewon in-house production from Sep 20263Q25 sales KRW 5.6bn, +32.3% YoY [S66][S25]
Pinecue Naproxen / Pinecue Ibuprofen syrupOTC analgesicsConsumer pain/fever2024–2025—

Pharmaceuticals — Circulatory & endocrine (chronic disease)

ProductDescriptionTargetLaunchKey data
Idalbi (이달비정) — Celltrion PharmAzilsartan medoxomil ARBHypertensionCo-sales from Jan 2026Co-promotion [S20]
Idalbi Clo (이달비클로정)Azilsartan + chlorthalidoneHypertensionCo-sales from Jan 2026[S20]
Idaldipine (이달디핀정)Azilsartan + amlodipine IMD combinationHypertensionLaunched Jan 2026; high-dose strengths reimbursed Feb 2026Lead product in ~KRW 2.5trn Korean hypertension market [S20][S21][S71]
Twinclo (트윈클로)Telmisartan + amlodipine + chlorthalidone (triple)HypertensionPlanned April 2026Own-developed [S21]
Dapacita-M SR (다파시타엠서방정)Dapagliflozin + sitagliptin + metformin (triple)Type 2 diabetes2,023[S72]
Tabarozet (타바로젯)Pitavastatin + ezetimibeDyslipidaemia—3Q25 sales KRW 4.9bn, +30.9% YoY [S66]
Tizipenon (티지페논정)Hypertriglyceridaemia agentHypertriglyceridaemia—[S73]
Uptava SR (업타바서방정)——Jun 2026[S74]

Pharmaceuticals — Digestive

ProductDescriptionTargetLaunchKey data
Potagel suspension (포타겔현탁액)Antidiarrhoeal (dioctahedral smectite class)DiarrhoeaLong-standingReported sales-volume No.1 for five consecutive years (company PR, 2025) [S74]
Pancreone tab 25000 (판크라원정)Pancreatin 400mg enteric film-coated tablet; 25,000 EP lipase units; 23.7% smaller than equivalent capsulesPancreatic exocrine insufficiency19 Oct 2026First tablet in a capsule-dominated Korean category [S26]
The Brew gel (더브루겔액)Squeezable anti-flatulentOTC digestiveOct 2026[S25]

OTC / Consumer health

ProductDescriptionTargetLaunchKey data
Colday series (콜대원 콜드/코프/노즈/키즈/나이트)Squeezable stick-pack cold syrups (acetaminophen-based and symptom variants)Consumers, children2015 (10th anniversary 2025)~KRW 30bn brand; Colday Kids KRW 9.2bn in 2022, No.1 children's cold medicine [S75][S76]; OTC division >KRW 40bn (2025) [S19]
New Vein (뉴베인액)OTC liquid (vein/circulation)Consumers—Wholesale 7-pack added 2025 [S74]
Curevan Foam Ag (큐어반 폼 Ag)Silver foam wound dressingWound care—[S74]

Health functional foods (Daewon Health / Daewon Healthcare)

Product / businessDescriptionKey data
Kkuljam Shot (꿀잠샷)Sleep-support HFFDriver of 1H26 HFF revenue KRW 20.7bn [S6]
Hair Collagen 3X (모발콜라겐3X)Hair/skin HFFDriver of 1H26 HFF growth [S6]
Albumin King / Amino King / Magnesium KingLiquid nutrition productsAlbumin King sold out five consecutive home-shopping slots (2025) [S9]; Magnesium King launched Sep 2026 [S25]
The Collagen 100, Astarooji (eye health), PDRN dual packageHFF line extensionsLaunched Jan 2026, Jan 2026, Sep 2026 [S74][S62][S32]
Jangdaewon Nature Plus (장대원)Organic-certified probioticExported to Hong Kong, Singapore, Philippines (2019) [S77]
Daewon Healthcare contract manufacturingODM/OEM HFF manufacturingCompany claims KRW 71.0bn contract-manufacturing revenue in 2024 [S19] — inconsistent with KRW 28.1bn consolidated HFF segment revenue; classification not reconciled

Cosmetics (SD Biotechnology)

Product lineShare of 2Q26 SD Biotech revenueNotes
Mask packs (SNP-heritage brands)79%Core line [S38]
Eye patches21%[S38]

Financial Narrative

Income statement

Revenue CAGR: FY2021–FY2025 4-year CAGR = 14.3%; FY2022–FY2025 3-year CAGR = 8.1% (computed).

Commentary. The five-year record has three distinct phases. (1) Pandemic/endemic surge (FY2021–FY2022): respiratory demand, Jincheon capacity and Colday OTC growth drove a 35% revenue jump in FY2022 and peak operating margin of 9.0%. (2) Diversification drag (FY2023–FY2024): revenue kept growing (+10%, +13.5%) helped by the 2023 reimbursement re-evaluation that restricted loxoprofen and pushed prescribers to Pelubi [S36], but margins compressed as Daewon Healthcare and then SD Biotech were consolidated and R&D rose. (3) Profit collapse (FY2025): revenue growth stalled (+1.2%), cost of sales rose KRW 21.8bn to KRW 332.6bn as lower-margin in-licensed products (AstraZeneca inhalers) entered the mix, SG&A rose KRW 8.4bn to KRW 245.5bn, and R&D expense rose to KRW 23.8bn [S1]. Operating income fell 87.6% to KRW 3.5bn and the company recorded a net loss for the first time in decades [S1]. The 3Q25 consolidated loss of KRW 10.4bn was the inflection low [S9].

1H26 update: revenue KRW 310.9bn (+3.1% YoY), operating income KRW 4.4bn (−45.3%), net income KRW 5.7bn (+308%, boosted by gains on disposal of investment assets) [S6]. SG&A rose 8.8% YoY owing to R&D and HFF marketing [S6]. 2Q26 was operating break-even (−KRW 9m) on revenue of KRW 152.8bn (+6.2% YoY) [S7]. Flagship Pelubi and Codaewon declined because of price cuts and an absent respiratory season, offset by Idalbi chronic-disease prescriptions and HFF [S6].

Balance sheet

Source: [S3 Valueline, DART-derived consolidated statements]. Borrowings exclude lease liabilities. Net debt = total borrowings − cash − short-term financial assets (computed). FY2025 borrowings comprise short-term borrowings 89.1, short-term bonds/CP 16.7, current portion of long-term debt 11.3, straight bonds 30.0, exchangeable bonds 15.0 and long-term borrowings 37.9 [S3].

30 June 2026: total assets 573.3; cash 23.7; short-term financial assets 43.0; total borrowings 186.6 (short-term borrowings 89.1, current portion of long-term debt 38.0, exchangeable bonds 15.2, long-term borrowings 44.3); equity 275.7; net debt ≈119.9 [S3]. The jump in the current portion (11.3 → 38.0) indicates the KRW 30bn straight bond has moved inside 12-month maturity — roughly two-thirds of gross debt is now short-dated.

Commentary. Gross debt rose 73% in three years (FY2022–FY2025) as the company funded the SD Biotech acquisition, loans to subsidiaries, the Magok building purchase and capex. The liability-to-equity ratio climbed from 82.3% (FY2022) to 105.0% (FY2024) [S10][S5] and 123.5% (FY2025, computed from [S3]; DS reports 143.6% and Valueline's indicator page 127.5% — definitional discrepancy). Borrowing dependence was ~31% of assets in FY2024 [S81]. Inventory reduction in FY2025 (−KRW 15.4bn) supported cash generation.

Cash flow

Sources: OCF FY2022–FY2024 [S4 Paasa]; FY2025 KRW 42.3bn OpenDART-verified [S80] (Paasa shows 43.6). Discrepancy: Kyobo shows FY2022 OCF of KRW 26bn vs Paasa 33.3 [S12]. Capex from DS [S10]; Valueline shows FY2025 PP&E additions of KRW 29.8bn plus intangible additions (largely capitalised development) of KRW 12.3bn [S3] — on that broader definition FY2025 FCF was ~KRW 0.2bn, and Valueline's own FCF metric is −KRW 4.7bn. Dividends: FY2022–FY2024 totals from [S58]; FY2025 from cash paid in 1H26 (KRW 5.35bn) [S3]. No buybacks identified; treasury shares carried at KRW 15.1bn (unchanged FY2022–FY2025) [S3]. D&A FY2025: depreciation KRW 18.7bn, amortisation KRW 5.1bn [S3].

1H26 note: TTM operating cash flow to June 2026 fell to KRW 18.2bn as working-capital movements reversed [S3].

Ratios

Sources: ROE [S10 DS] (Valueline shows FY2025 ROE −0.5%); all other ratios computed from [S3] balance sheet and [S4][S1] income data using year-end balances. FY2021 ROE was 3.2% [S79].

Interest coverage: FY2025 operating income / interest expense = 3.5 / 7.2 = 0.5x [S3]; TTM June 2026 ≈ 0.0x. ROIC: Kyobo shows 11.9% (FY2022) and 9.8% (FY2023) [S12]; Valueline shows −1.6% (FY2025) [S3].

Ratio commentary. Every return metric has deteriorated for three consecutive years. Coverage below 1x in FY2025 and TTM means operating profit no longer covers interest; liquidity is being supported by operating cash flow, asset sales (investment disposals in 1H26) and refinancing. The cash conversion cycle improved in FY2025 on inventory reduction, but at ~120 days remains long, reflecting syrup/seasonal stock and in-licensed product inventory.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityBusinessDaewon stakeAcquiredNotes

Daewon Healthcare (대원헬스케어, ex-Kukdong H-Pharm)

HFF contract manufacturing (ODM/OEM), Yesan, South Chungcheong

83.5% at acquisition

May 2021 (KRW 14.1bn)

KRW 0.3bn impairment reversal recognised in FY2025 [S48]

SD Biotechnology (에스디생명공학, KOSDAQ 217480)

Cosmetics (mask packs, eye patches); HFF production division sold, treated as discontinued

72.9%

Dec 2023 (KRW 40.0bn)

Trading suspended since Mar 2023; KRX delisting decision Oct 2026, under injunction [S53][S38]

Daewon Meditech (ex-Delight)

Hearing aids

—2011

Effectively wound down; assets KRW 44 thousand, zero revenue in 2023 [S41]

“—” = not publicly disclosed.

Revenue by Segment and Revenue by Segment (%)

Segment (KRW Bn)FY2024FY2025

Pharmaceuticals revenue (KRW Bn)

536.1542.9

Health functional foods revenue (KRW Bn)

28.136.1

Cosmetics revenue (KRW Bn)

34.530.1

Consolidated revenue (KRW Bn)

598.2605.4

Pharmaceuticals share of consolidated revenue (%)

89.689.7

HFF share of consolidated revenue (%)

4.76.0

Cosmetics share of consolidated revenue (%)

5.85.0

Revenue by Segment

Therapeutic area (KRW Bn)FY2024FY2025

Respiratory

114.7122.7

Antipyretic / analgesic / anti-inflammatory

112.4110.4

Circulatory and endocrine (chronic)

127.4123.3

Digestive

50.752.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment

Metric (KRW Bn)FY2024

Separate (parent) operating income (KRW Bn)

40.9

Consolidated subsidiaries operating income (KRW Bn)

-12.9

Consolidated operating income (KRW Bn)

28.2

Results by Segment (FY2021–FY2025)

SD Biotechnology metric (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

124.792.946.934.530.1

Operating income (KRW Bn)

-34.8-41.0-13.7-9.2-6.3

Net income (KRW Bn)

-45.1-75.0-6.0-14.8-7.5

Quarter Metric Details

Quarter metric (KRW Bn)1Q252Q253Q254Q251Q262Q26

Revenue (KRW Bn)

157.8143.9143.9159.8158.1152.8

Operating income (KRW Bn)

9.4-1.4-10.45.84.40.0

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

354.2478.9527.0598.2605.4

Revenue growth YoY (%)

14.935.210.013.51.2

Gross profit (KRW Bn)

176.5237.9254.2287.3272.8

Operating income (KRW Bn)

19.443.032.228.23.5

EBITDA (KRW Bn)

37.062.050.048.030.0

Net income consolidated (KRW Bn)

6.630.723.59.0-4.0

Net income attributable to parent (KRW Bn)

7.231.923.914.2-1.4

EPS basic (KRW)

3291,4541,078634-62

Gross margin (%)

49.849.748.248.045.1

Operating margin (%)

5.59.06.14.70.6

EBITDA margin (%)

10.412.99.58.05.0

Net margin (%)

1.96.44.51.5-0.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet

MetricFY2022FY2023FY2024FY2025

Total assets (KRW Bn)

453.6508.0583.4613.7

Cash and cash equivalents (KRW Bn)

27.030.017.147.2

Short-term financial assets (KRW Bn)

20.40.229.329.9

Short-term debt incl. current portion and short-term bonds (KRW Bn)

63.4110.6120.7117.1

Long-term debt incl. bonds (KRW Bn)

52.134.663.682.9

Total borrowings (KRW Bn)

115.5145.2184.3200.0

Net debt (KRW Bn)

68.1115.0137.9122.9

Total liabilities (KRW Bn)

204.8243.7298.8339.1

Total equity (KRW Bn)

248.8264.3284.6274.6

Equity attributable to parent (KRW Bn)

250.9266.2275.3265.9

Goodwill (KRW Bn)

11.37.35.56.0

Total intangibles incl. goodwill (KRW Bn)

40.141.554.862.5

Capitalised development costs (KRW Bn)

15.118.120.125.8

Inventories (KRW Bn)

91.8105.1113.297.8

Trade receivables (KRW Bn)

62.570.673.477.1

Working capital (current assets less current liabilities) (KRW Bn)

79.226.656.840.3

Cash Flow

MetricFY2022FY2023FY2024FY2025

Operating cash flow (KRW Bn)

33.351.730.042.3

Capex PP&E (KRW Bn)

8.012.034.034.0

Free cash flow OCF less PP&E capex (KRW Bn)

25.339.7-4.08.3

Cash dividends declared for the fiscal year (KRW Bn)

7.36.46.45.4

Share buybacks (KRW Bn)

0.00.00.00.0

Margin Analysis (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE (%)

13.69.25.2-1.9

ROA year-end assets (%)

6.84.61.5-0.7

Current ratio (%)

161.8114.6128.3118.6

Total borrowings to equity (%)

46.454.964.872.8

Total liabilities to equity (%)

82.392.2105.0123.5

Net debt to EBITDA (x)

1.12.32.94.1

Asset turnover (x)

1.061.041.030.99

Days sales outstanding (days)

47.648.944.846.5

Days inventory outstanding (days)

139.0140.6132.9107.3

Days payables outstanding (days)

29.728.024.533.2

Cash conversion cycle (days)

156.9161.5153.2120.6

Revenue by Region (%)

Geographic metricFY2021FY2023FY2025

Overseas share of revenue (%)

2.872.004.29

Share Price and Market Valuation

Price metric (KRW)FY2022FY2023FY2024FY2025

Year-end share price (KRW)

18,75015,66014,25011,950

Year-end market capitalisation (KRW Bn)

411.8347.5319.6268.0

Valuation Snapshot

MultipleValueSource / basis

P/E (TTM)

66.9–69.5x

[S3][S121]

P/B

0.65–0.67x

[S3][S121]

P/S (TTM)

0.29x

[S3]

EV/EBITDA (TTM Jun 2026)

7.6x

[S3]

EV/Sales (TTM)

~0.49x (EV ≈ KRW 304bn: mkt cap 175.6 + net debt 119.9 + minorities 8.1; TTM revenue 614.6)

Computed from [S3]

Forward P/E (12m)

~12.0x

[S2]

Analyst Ratings & Targets

BrokerDateRatingTarget price (KRW)Key view

Consensus (5 brokers)

Oct 2026

—14,800—

DS Investment & Securities

26 May 2026

Buy (initiation)

16,000

FY2026E revenue 627.2bn, OP 19.4bn, EPS 756; Idalbi family to drive growth

SK Securities

19 May 2026

Buy

15,000

Subsidiary losses narrowing; R&D optionality

Kiwoom Securities

28 Jan 2026

Buy

15,000 (cut 11.8%)

Subsidiary turnaround needed

Kyobo Securities

17 May 2024

Buy

20,000

Historic reference

Dividend metric

Dividend metricFY2023FY2024FY2025

Dividend per share (KRW)

300300250

Analyst Conclusions

Guidance and expectations

Management has given qualitative guidance only: diversify into chronic disease and HFF while improving profitability through cost efficiency in 2H26 [S6]. Sell-side FY2026 expectations: DS revenue KRW 627.2bn (+3.6%) and OP KRW 19.4bn [S10]; SK Securities had earlier projected FY2026 OP of ~KRW 31.4bn [S9], since tempered by a 1Q26 miss [S8]. 1H26 delivered only KRW 4.4bn of OP, so FY2026 consensus appears to require a strong 4Q respiratory season.

Bull case

  1. Chronic pivot gains traction: Idalbi family and Twinclo, plus Tabarozet/Sinbaro growth (+30%+ in 3Q25), lift circulatory/endocrine toward 35% of sales by 2028 and dampen seasonality [S21][S66].

  2. Padoprazan approval (ERD/NERD Phase 3 in parallel) would give Daewon a second proprietary drug in a ~KRW 400bn P-CAB market [S62][S32].

  3. Deep value with optionality: 0.66x P/B and 7.6x EV/EBITDA with ~3% yield; obesity assets (quadruple agonist) demonstrated the market will pay for credible data (June 2026 limit-up) [S3][S107].

Bear case

  1. Structural margin damage: Pelubi's price cut plus 10 pelubiprofen competitors and the sector generic reform hit two of Daewon's three pillars simultaneously [S36][S109][S106].

  2. Balance-sheet strain: interest cover <1x, debt ratio >120%, two-thirds of debt short-dated; SD Biotech may require more cash despite delisting [S3][S53].

  3. Execution record: two diversification deals have destroyed value; co-promotion growth carries lower gross margins (FY2025 cost of sales +7%) [S41][S1].

Key catalysts and monitorables (next 12 months)

  • 3Q26 results (mid-Nov 2026) and 4Q26 respiratory season strength.

  • Court ruling on SD Biotech's delisting injunction and any further Daewon funding.

  • Padoprazan ERD/NERD Phase 3 enrolment progress and topline timing.

  • Pelubi volume retention post price cut; pace of second-wave generic launches.

  • Idalbi/Idaldipine and Twinclo prescription ramps (UBIST monthly data).

  • Implementation details of the generic-price reform for Daewon's portfolio; any R&D-intensity premiums.

  • CVC establishment and investments; refinancing of the straight bond.

  • FY2026 dividend (policy floor of 15% of separate NI).

Analyst verdict

Daewon Pharmaceutical is a capable commercial organisation trapped in a weak profit structure. Its core competence — a primary-care salesforce plus syrup manufacturing scale — produced a genuine growth story between 2021 and 2024, lifting revenue from KRW 354bn to KRW 598bn. That story has now been interrupted from three directions at once. First, regulation: the Pelubi price cut and the generic-price reform reduce the value of exactly the kind of portfolio Daewon owns. Second, capital allocation: SD Biotechnology has absorbed KRW 60bn of acquisition and asset-purchase capital while shrinking and moving toward delisting, and consolidated losses there have turned a solidly profitable parent into a break-even group. Third, mix: growth is increasingly coming from in-licensed products (AstraZeneca, Celltrion) that carry thinner margins, so revenue gains no longer translate into profit.

The valuation already reflects much of this — the shares trade at roughly two-thirds of book value, under 0.5x EV/sales and about 7.6x trailing EV/EBITDA, with a ~3% dividend yield — and the sell side remains uniformly constructive with targets near KRW 15,000. But the evidence for a turnaround is not yet in the numbers: 1H26 operating profit was only KRW 4.4bn, interest cover is below 1x, and the balance sheet has limited room for further subsidiary support.

The investment case therefore hinges on three binary-ish events over 12–24 months: a normal-to-strong respiratory season restoring the cash engine; containment of SD Biotech without further large cash calls; and padoprazan Phase 3 success. The obesity programmes are early-stage options, not value drivers. On balance, Daewon screens as a cheap but fragile special-situation. Positioning should be contingent on evidence of margin recovery in 4Q26 results.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleBackground

Baek Seung-ho (백승호)

Chairman; inside director

Eldest son of founder; managed the company with his brother for ~40 years; age ~69 (2025)

Baek Seung-yeol (백승열)

Vice Chairman; co-CEO; Chair of the Board

Born 1959; Seoul National University (agricultural biology); CEO since 1996

Baek In-hwan / Jonathan In Baek (백인환)

President; co-CEO (since Jan 2024); inside director

Born 1984; economics, Brandeis University; joined 2011 as deputy manager in Strategy Office; overseas business, healthcare, new growth, marketing head; president from end-2022

Bang Yong-won (방용원)

Outside director; Audit Committee chair

Former vice chairman, EY Hanyoung

Lee Dong-hee (이동희)

Outside director

Vice chairman, Korea Pharmaceutical Traders Association

Cho Joo-yeon (조주연)

Outside director

Attorney, Shin & Kim (Sejong)

Executive Leadership Team

NameRoleNotes

Baek In-yeong (백인영)

Head of Healthcare Business Division; CEO of SD Biotechnology since Nov 2025

Vice Chairman's eldest son; joined 2019; ran OTC/HFF

Kim Joo-il (김주일)

Vice President, R&D Division

Presented quadruple-agonist strategy

Lee Kyung-joon (이경준)

Head of Central Research Institute (Executive Director)

Obesity pipeline timelines

Park Jo-hyun (박조현)

Head of CHC (Managing Director)

Joined Aug 2025 from Chong Kun Dang Health

Lee Jeong-hee (이정희)

Head of OTC (Managing Director)

—

Major Shareholders

HolderStakeAs of

Largest shareholder and related parties (Baek family et al.)

37.69%

End-2025

Baek Seung-yeol

11.58% (Dealsite) / 14.31% (IB Tomato)

Q3 2023 / early 2024

Baek Seung-ho

9.84%

Q3 2023

Baek In-hwan

5.93%

Q3 2023

Baek In-yeong

2.98%

Sept 2023

Fidelity Management & Research and affiliates

9.85%

May 2024

Minority shareholders (19,787 holders)

47.85%

End-2025

Foreign ownership

13.7%

Jan 2026

Competitive Landscape

Competitors by Segment

SegmentNamed competitorsPositioning notes

Antitussive-expectorants

Ahn-Gook Pharmaceutical (Synatura), Yuhan Corporation (Coughu)

Daewon's Codaewon series held 63.7% of the dihydrocodeine-combination market (KRW 151.2bn total) in 2024

NSAIDs / pelubiprofen

Youngjin Pharm (Pelps), Huons (Peloen), Chong Kun Dang (Belupen), Donggu Bio (Pelbifen), Hana Pharm, HLB Pharm, Dasan, Alico

~KRW 50bn pelubiprofen market; generics held ~10% share in 1Q25

P-CAB (pipeline)

HK inno.N (K-CAB), Daewoong (Fexuclue), Onconic Therapeutics

Padoprazan would be Korea's fourth P-CAB; market ~KRW 400bn

Hypertension

Boryung (Kanarb family), Hanmi Pharm (Amosartan), Celltrion Pharm (partner)

Daewon is a new entrant via co-promotion

Asthma inhalers

Kolon Pharm (Foster, Trimbow), Hanmi (Flutelol), Huons (Zephirus)

Few domestic players due to device barriers

HFF

Chong Kun Dang Health, GC Wellbeing

Daewon is sub-scale

Cosmetics

Dongkook Pharmaceutical (Centellian24)

Dongkook's healthcare/cosmetics >50% of revenue

Mid-cap peer set (revenue)

Ildong Pharmaceutical, Jeil Pharmaceutical, Celltrion Pharm, Kwang Dong, Daewoong

Comparable scale or larger

Peer Comparison FY2025

MetricDaewonCelltrion Pharm (separate)Kwang DongDaewoong

Revenue (KRW Bn)

605.4536.41,659.51,570.8

Revenue growth YoY (%)

1.212.21.110.4

Operating income (KRW Bn)

3.556.131.0196.8

Operating margin (%)

0.610.51.912.5

Company Snapshot

$426M

Revenue

1,349

Employees

1958

Founded

Seoul, South Korea

Headquarters

SWOT Analysis

Strengths

  • Codaewon series Rx grew from KRW 56.6bn (2022) to KRW 93.2bn (2024) [S19]; 63.7% share of its combination segment [S69].
  • Pelubi was Korea's No.1 NSAID by prescriptions from 2018, with 2025 Rx of KRW 57.2bn [S19][S36].
  • Jincheon smart factory gives large liquid-dosage capacity — cited as key to Codaewon S growth [S46].
  • Multinational validation: AstraZeneca chose Daewon to distribute Symbicort/Pulmicort [S37].
  • Operating cash flow remained positive through the profit downturn (FY2025 KRW 42.3bn) [S80].
  • KCGS ESG rating upgraded to A in 2025 (Social A+) [S60].

Weaknesses

  • FY2025 operating margin 0.6% and first net loss (−KRW 4.0bn) [S1].
  • Interest coverage 0.5x in FY2025 [S3].
  • Liability-to-equity rose from 82.3% (FY2022) to 105.0% (FY2024) and above 120% (FY2025) [S10][S3].
  • SD Biotech: revenue down from KRW 124.7bn (2021) to KRW 30.1bn (2025), losses every year; facing delisting [S38][S53].
  • Expensed R&D only ~3.9% of revenue (FY2025) [S1]; capitalisation ratio ~8% [S98].
  • Family control of both CEO and board-chair roles; half the board are family members [S18].

Opportunities

  • Idalbi/Idaldipine and Twinclo give access to a ~KRW 2.5trn hypertension market [S21].
  • Padoprazan in parallel ERD/NERD Phase 3 plus H. pylori and NSAID-ulcer label extensions [S62].
  • Quadruple agonist showed >50% weight loss vs control in mice and attracted strong market interest (limit-up) [S63][S107].
  • HFF momentum: 1H26 HFF revenue KRW 20.7bn on Kkuljam Shot and Hair Collagen 3X [S6].
  • Export growth: overseas share rose to 5.71% in 1H25 from 2.00% in 2023 [S82]; Vietnam engagement [S32].
  • R&D-linked generic pricing premiums under the 2026 reform could reward higher R&D intensity [S115].

Threats

  • Pelubi price cut of 46.7% (tablet) / 23.0% (SR) from May 2026 and 10 competing pelubiprofen products [S36][S109].
  • Sector generic-price reform lowering ceilings for generics and off-patent drugs [S106].
  • Respiratory seasonality — weak seasons depressed 3Q25 and 1H26 [S6][S66].
  • SD Biotech delisting and possible further capital calls (Daewon has deferred any decision on additional funding) [S53].
  • Intensifying P-CAB competition (three approved domestic agents ahead of padoprazan) [S92].
  • Refinancing risk: ~two-thirds of borrowings short-dated at June 2026 [S3].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
12 May 2025DW4421 Phase 3 IND filed (ERD, NERD) [S99]Second new drug advances
15 May 20251Q25: revenue 157.8bn (−0.3%), OP 9.4bn (−36.9%) [S67]Margin erosion begins
May 2025Supreme Court rules for Pelubi generic challengers [S57]Loss of exclusivity
2 Jun 2025Governance report: 53.3% core-indicator compliance [S58]Governance improvement
30 Jun 2025KRX Corporate Review Committee recommends SD Biotech delisting [S103]Subsidiary risk
25 Jul 2025KOSDAQ Market Committee decision on SD Biotech; objection period [S104]Subsidiary risk
14 Aug 20252Q25: revenue 143.9bn (+4.3%), operating loss 1.4bn [S68]Cost of goods up 9.3%
Aug 2025New CHC head hired from Chong Kun Dang Health [S87]Consumer push
Aug 2025SD Biotech 60% capital reduction announced [S93]Clean-up of KRW 106.3bn deficit
Sep 2025Codaewon Plus approved; Colday 10th anniversary [S69]Respiratory line extension
27 Oct 2025NERD Phase 3 IND approved [S62]Pipeline
Nov 20253Q25: revenue 143.9bn (−8.3%), OP −10.4bn [S9]Trough quarter
Nov 2025Baek In-yeong appointed SD Biotech CEO; 8-month improvement period [S59]Family accountability
21 Nov 2025KCGS ESG rating upgraded to A (S: A+) [S60]ESG
28 Nov 2025Drug-pricing reform plan reported to HIPDC (generic ceiling cut) [S105]Sector headwind
4 Dec 2025Pelubi infringement suit finally lost [S61]IP closure
6 Jan 2026Celltrion Idalbi co-promotion [S20]Chronic pivot
12–16 Jan 2026DW4421 H. pylori Phase 1 approval; NERD Phase 3 kick-off [S92][S62]Pipeline
28 Jan 2026Kiwoom cuts target price 11.8% (to KRW 15,000) [S11]Sell-side caution
4 Feb 202635% chronic-disease revenue target for 2028 disclosed [S21]Strategy
25 Feb 2026Purchase of SD Biotech Magok building (KRW ~20bn) [S53]Capital to subsidiary
18 Mar 2026FY2025: revenue 605.4bn, OP 3.5bn (−87.6%), net loss 4.0bn [S1]First annual loss
19 Mar 2026SD Biotech impairment KRW 0.6bn; Daewon Healthcare reversal KRW 0.3bn [S48]Subsidiary valuation
26 Mar 2026HIPDC adopts drug-price reform; generic ceilings to fall [S106]Sector headwind
2 Apr 2026Supreme Court dismisses Pelubi price suit [S36]Price cut confirmed
1 May 2026Pelubi −46.7%, Pelubi SR −23.0% price cut effective [S36]Revenue/margin hit
18–19 May 20261Q26: revenue 158.1bn (+0.1%), OP 4.4bn (−53.4%), below consensus [S8]Earnings miss
26 May 2026DS initiates Buy, TP KRW 16,000 [S10]Sell-side support
4–8 Jun 2026Quadruple-agonist preclinical data at ADA 2026; stock limit-up then +19.7% next session [S63][S64][S107]Re-rating catalyst
12 Jun 2026Donggu Bio Pelubi generic approved; IR held [S102]Generic pressure
17 Jun 2026Obesity timelines: FIH 2028 (quadruple), oral semaglutide human trials 2027 [S88]Pipeline visibility
4 Aug 2026CVC plan for digital health reported [S28]New initiative
7 Aug 20261H26: revenue 310.9bn (+3.1%), OP 4.4bn (−45.3%), NI 5.7bn; 2Q26 OP −9m [S6][S7]Margin pressure persists
14 Sep 2026Vietnamese government/industry delegation visits Jincheon [S32]Export ambitions
15 Sep 2026IR event notice [S2]Investor engagement
21 Sep 2026Sinbaro in-house production begins [S25]Margin initiative
28 Sep 2026Privitus pouch production restored, supply from Oct [S25]Respiratory supply
Oct 2026SD Biotech delisting decision; injunction filed; Daewon reaffirms control [S53]Subsidiary risk
8–19 Oct 2026Pelubi post-op pain data at KOA 2026; The Brew gel and Pancreone tab launches [S25][S26]Product flow

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Revenue by Segment: Pharmaceuticals revenue rose from KRW 536.1 Bn in FY2024 to KRW 542.9 Bn in FY2025.
Daewon Pharmaceutical Co., Ltd. — Revenue by Segment
Series (KRW Bn)FY2024FY2025
Pharmaceuticals revenue536.1542.9
Health functional foods revenue28.136.1
Cosmetics revenue34.530.1
Consolidated revenue598.2605.4
Respiratory114.7122.7
Antipyretic / analgesic / anti-inflammatory112.4110.4
Circulatory and endocrine (chronic)127.4123.3
Digestive50.752

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1Dealsite, "대원제약, 외형 성장에도 수익성 급락…순손실 전환", 18 Mar 2026 (FY2025 results, segments) (dealsite.co.kr)
  2. S2Butler.works, 대원제약 company page (FY2021–25 summary, consensus, filings list) (butler.works)
  3. S3Valueline/DataHero (DART-derived consolidated BS, IS, CF, indicators; accessed 20 Oct 2026) — ; /income/003220 ; /cashflow/003220 ; /investment/003220 (valueline.co.kr)
  4. S4Paasa, Daewon Pharmaceutical statements FY2021–FY2025 (paasa.com)
  5. S5News Space, "Daewon Pharmaceutical Risk (Part 1)", 25 Apr 2025 (newsspace.kr)
  6. S6Medigate News, 1H26 results, 8 Aug 2026 · Asia Economy English
  7. S7Dealsite, 2Q26 results, 7 Aug 2026 (dealsite.co.kr)
  8. S8SK Securities, "1Q26 Re", 19 May 2026 (stock.pstatic.net)
  9. S9SK Securities, "겨울의 강자", 28 Nov 2025 (file.alphasquare.co.kr)
  10. S10DS Investment & Securities, 26 May 2026 · summary
  11. S11Kiwoom Securities, 28 Jan 2026 (bbn.kiwoom.com)
  12. S12Kyobo Securities, 17 May 2024 (stock.pstatic.net)
  13. S14KIR / Korea Technology Credit technical report, 4 Oct 2024 (stock.pstatic.net)
  14. S16Dealsite, CEO appointment, 19 Jan 2024 (dealsite.co.kr)
  15. S18CEO Score Daily, board composition, Aug 2025 (ceoscoredaily.com)
  16. S19Daewon IR, 3Q25 management presentation, Nov 2025 (file.alphasquare.co.kr)
  17. S20Medical Times / Kuki News, Celltrion co-promotion, 6 Jan 2026 · kukinews.com
  18. S21Money Today, chronic disease 35% target, 4 Feb 2026 (mt.co.kr)
  19. S23ETF Shopping (DART FY2025 business report extracts: employees, ownership, address) (etfshopping.com)
  20. S25Daewon Pharmaceutical newsroom (daewonpharm.com)
  21. S26Financial News, Pancreone tab launch, 19 Oct 2026 (fnnews.com)
  22. S27Medifo News, TOP50 pharma 2025 (medifonews.com)
  23. S28StockHub (Seoul Economy), CVC plan, 4 Aug 2026 (stockhub.kr)
  24. S30The VC company profile (thevc.kr)
  25. S31Simply Wall St profile (simplywall.st)
  26. S32AlphaSquare stock summary/news feed (alphasquare.co.kr)
  27. S33Remember career profile (career.rememberapp.co.kr)
  28. S34Medigate News, 2020 recruitment fair (medigatenews.com)
  29. S35FN News / News1, 1Q22 Rx, Apr 2022 (fnnews.com)
  30. S36Daily Pharm, Pelubi price cut, 14 Apr 2026 and 27 Apr 2026 · dailypharm.com
  31. S37Dealsite / Medifo / Daily Pharm, AstraZeneca partnership, Feb–Jun 2025 · medifonews.com
  32. S38Butler.works, SD Biotechnology page (butler.works)
  33. S39eToday, 12 Mar 2007 (etoday.co.kr)
  34. S40Herald Economy, padoprazan as second new drug, Jan 2026 (heraldk.com)
  35. S41Dealsite, diversification M&A history, 15 May 2024 (dealsite.co.kr)
  36. S42Daily Pharm, Colday US export version, Jul 2019 (m.dailypharm.com)
  37. S43Kuki News interview, Apr 2016 (kukinews.com)
  38. S44Daily Pharm, export figures 2018 (m.dailypharm.com)
  39. S45Money Today interview with Choi Tae-hong, Sep 2020 (mt.co.kr)
  40. S46Daily Pharm / Medifo, Codaewon S >KRW 70bn, Jan 2025 (dailypharm.com)
  41. S47Daily Pharm, inhaler line-up, Feb 2025 (m.dailypharm.com)
  42. S48Daily Pharm, subsidiary impairments, 19 Mar 2026 (dailypharm.com)
  43. S49Sidae, Baek In-hwan president, Dec 2022 (sidae.com)
  44. S50IBK Securities, Nov 2023 (file.alphasquare.co.kr)
  45. S51Medigate / Daily Pharm, Daewon Healthcare rename, 7 Jun 2023 (medigatenews.com)
  46. S52Daily Pharm, share gifts, Nov 2023 / Sep 2023 · dailypharm.com
  47. S53Daily Pharm, SD Biotech normalisation and delisting, 8 Oct 2026; Magok purchase, 26 Feb 2026 · dailypharm.com
  48. S54The Value News, Apr 2024 (thevaluenews.co.kr)
  49. S55Medifo News, DW4421 Phase 2/Unovia, May 2025 (medifonews.com)
  50. S56Daily Pharm, first loss in 3 years, Aug 2024 (dailypharm.com)
  51. S57Daily Pharm, Pelubi generic share/Supreme Court, May 2025 (dailypharm.com)
  52. S58Dealsite, governance and dividend policy, 24 Jun 2025 (dealsite.co.kr)
  53. S59Daily Pharm, Baek In-yeong to SD Biotech, 28 Nov 2025 (m.dailypharm.com)
  54. S60Daily Pharm, KCGS A rating, 21 Nov 2025 (dailypharm.com)
  55. S61Daily Pharm, infringement suit loss, 4 Dec 2025 (dailypharm.com)
  56. S62Kuki News, NERD Phase 3 kick-off, 16 Jan 2026 (kukinews.com)
  57. S63Biospectator / Daily Pharm, ADA 2026 quadruple agonist, 4 Jun 2026 · dailypharm.com
  58. S64StockHub, limit-up, 5 Jun 2026 (stockhub.kr)
  59. S65Dealsite, 1Q24 results, 16 May 2024 (dealsite.co.kr)
  60. S66Kormedi, 9M25 cumulative results (kormedi.com)
  61. S67Dealsite, 1Q25 results, 15 May 2025 (dealsite.co.kr)
  62. S68Dealsite, 2Q25 results, 14 Aug 2025 (dealsite.co.kr)
  63. S69Daily Pharm, Codaewon Plus / 63.7% share, 30 Sep 2025 (dailypharm.com)
  64. S70Medifo News article list (product launches) (medifonews.com)
  65. S71Daily Pharm, Idaldipine high-dose listing, 3 Feb 2026 (m.dailypharm.com)
  66. S72Daily Pharm related-article list (Dapacita-M SR) (dailypharm.com)
  67. S73Jasoseol company insight (secondary; strategy/ESG targets) (jasoseol.com)
  68. S74Medifo News article list 2025–2026 (medifonews.com)
  69. S75Money Today, Nov 2023 (Colday Kids) (mt.co.kr)
  70. S76Hanwha Investment & Securities, Nov 2022 (file.alphasquare.co.kr)
  71. S77Kormedi, Hong Kong probiotic launch (2019) (kormedi.com)
  72. S78Sangsangin Securities, Feb 2024 (file.alphasquare.co.kr)
  73. S79eBest (LS) Investment & Securities reports, Nov 2021, Aug 2022, Jan 2023 · file.alphasquare.co.kr
  74. S80Bullstory, OpenDART-verified FY2025 comparison (bullstory.io)
  75. S81IB Tomato, "확장 전략이 독", 13 May 2025 (newstomato.com)
  76. S82The Value News, Oct 2025 (thevaluenews.co.kr)
  77. S83Medifo News, 2025 recruitment (sites/functions) (medifonews.com)
  78. S84IntuitionLabs company profile (intuitionlabs.ai)
  79. S85Dealsite, SD Biotech HFF plant sale, 20 Mar 2026 (dealsite.co.kr)
  80. S86Altss corporate investor profile (altss.com)
  81. S87Daily Pharm, CHC head appointment, 16 Aug 2025 (dailypharm.com)
  82. S88Hankyung, obesity timelines, 18 Jun 2026 (hankyung.com)
  83. S89IB Tomato, cousin succession, 2024 (newstomato.com)
  84. S90IB Tomato, inheritance tax, 3 Jun 2024 (newstomato.com)
  85. S91Kuki News interview with Baek Seung-yeol, Apr 2016 (kukinews.com)
  86. S92Daily Pharm, H. pylori combination Phase 1, 20 Jan 2026 (dailypharm.com)
  87. S93Dealsite, SD Biotech capital reduction, Aug 2025 (dealsite.co.kr)
  88. S94KIR technical report, Oct 2024 (12 blockbusters) (stock.pstatic.net)
  89. S95Biospectator, DW-1022 Phase 1 IND approval (biospectator.com)
  90. S96Medifo News, AGORA WEEK, 7 Oct 2026 (medifonews.com)
  91. S97The Value News, pipeline and R&D 8.68%, early 2025 (thevaluenews.co.kr)
  92. S98IB Tomato, intangible capitalisation and pipeline, 2025 (newstomato.com)
  93. S99Hankyung, DW4421 Phase 2 results, 12 May 2025 (hankyung.com)
  94. S100Metro Seoul, pipeline overview, Jan 2025 (metroseoul.co.kr)
  95. S101Metro Seoul, DW-4301/4902/4121, Jan 2025 (metroseoul.co.kr)
  96. S102Daily Pharm, Donggu Bio generic approval, 12 Jun 2026 (dailypharm.com)
  97. S103Cosin Korea, SD Biotech delisting recommendation, 30 Jun 2025 (cosinkorea.com)
  98. S104Aju News, delisting procedure, 28 Jul 2025 (ajunews.com)
  99. S105Dealsite, pricing reform plan, Dec 2025 (dealsite.co.kr)
  100. S106Daily Pharm, HIPDC reform adoption, 27 Mar 2026 (dailypharm.com)
  101. S107Aju Business Daily via Daum, +19.66% on 8 Jun 2026 (v.daum.net)
  102. S108Medical Times, antitussive market history (medicaltimes.com)
  103. S109Daily Pharm, pelubiprofen market 10 products (dailypharm.com)
  104. S110Business Hankook, pharma diversification leaders, May 2025 (bizhankook.com)
  105. S111MTN, Dongkook Pharmaceutical, Jul 2026 (news.mtn.co.kr)
  106. S112Dealsite, Celltrion Pharm FY2025, 5 Feb 2026 (dealsite.co.kr)
  107. S113HuffPost Korea, FY2025 pharma operating profits (huffingtonpost.kr)
  108. S114Mirae Asset Daewoo report, Dec 2016 (securities.miraeasset.com)
  109. S115Daily Pharm desk column, reform details, 27 Jul 2026 (dailypharm.com)
  110. S116News Tomato, 40% draft, 14 Jan 2026 (newstomato.com)
  111. S117Medical Times, Daewon response to price cuts, 18 May 2026 (medicaltimes.com)
  112. S118iNews24, Potagel recall, Nov 2023 (inews24.com)
  113. S119Daily Pharm, 2025 patent review, 22 Dec 2025 (dailypharm.com)
  114. S120Daily Pharm, Pelubi price suit stay, Jan 2026 (dailypharm.com)
  115. S121Judal AI analysis snapshot, 11 Oct 2026 (judal.co.kr)
  116. S122Google Finance, 003220:KRX (google.com)
  117. S123IB Tomato credit signal (NICE commentary), Oct 2023 (newstomato.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.